HALL COSMOS

14.00-19.00

Registration

15.00-16.30

EADO Board Meeting

HALL COSMOS

16.30-18.30

Pre-Congress Session: Advances in melanoma therapeutics: new studies, new agents

Chair: A. Hauschild (Germany), H. Gogas (Greece), A. Polyzos (Greece)

Ipilimumab - Tremelimumab 
J.J. Grob, France

PLX4032 and MEK inhibitors
A. Hauschild, Germany

MAGE 3 vaccination
J. Kirkwood, USA

Immunotherapy with  L19-Interleukin-2 [ L19-IL-2]
C. Garbe, Germany

Bevacizumab 
H. Gogas, Greece

Antiangiogenic factors in melanoma
D. Bafaloukos, Greece

C-kit inhibitors
S. Ugurel, Germany

Electrochemotherapy
A. Testori, Italy

HALL COSMOS

19.00-19.30

Opening Ceremony

19.30-20.00

Opening Keynote Lecture
Chair: J.J. Grob (France), A. Katsambas (Greece)

Molecular classification of melanocytic neoplasia
B. Bastian (USA)

20.00

Welcome Reception

HALL COSMOS

08.00-09.30

Plenary Session I: Primary prevention of melanoma: are we making progress?
Chairs: V. Bataille (UK), A. Halpern (USA), D. Whiteman (Australia

Trends in incidence of cutaneous malignant melanoma in Europe: analysis of population based cancer registry data
C. Holterhues (The Netherlands)

Genes, sunlight and the origins of cutaneous melanoma
D. Whiteman (Australia)

Is primary prevention having an impact on disease incidence?
A. Halpern (USA)

The vitamin D controversy: implications for melanoma control
S. Krüger-Krasagakis (Greece)

Sunbeds and melanoma
V. Bataille (UK)

HALL COSMOS

09.30-10.00

Keynote address I
Chair: C. Garbe (Germany), A. Stratigos (Greece) 

Personalizing Melanoma Medicine in the Molecular Era
H. Tsao (USA)

10.00-10.30

Break

HALL COSMOS

10.30-12.00

Plenary Session II: Optimizing secondary prevention of melanoma
Chairs: J.J. Grob (France), M. Binder (Austria), D. Ioannides (Greece

New concepts in nevogenesis
I. Zalaudek (Austria)

The challenge of congenital nevi: remove or not remove?
A. Marghoob (USA)

How to manage dysplastic nevi?
J. Malvehy (Spain)

Diagnostic monitoring in high-risk patients: is it cost-effective?
M. Binder (Austria)

Early detection of thick melanomas: mission impossible?
J.J. Grob (France)

HALL COSMOS

12:15-13.45

Lunch Session I: Sun protection and melanoma
Sponsored by: 

Chair: T. Luger (Germany), G. Avgerinou (Greece), S. Alper (Turkey)

An up date on UV-induced carcinogenesis
S. Beissert (Germany)

Sunscreens and melanoma: an on-going controversy
A. Sober (USA)

The value of melanin as a sunscreen
N. Kollias (USA)

New approaches in photoprotection: alpha-Melanotropin (αMSH) analogs
V. del Marmol (Belgium)

New approaches in photoprotection: DNA repair agents
M. Kosmadaki (Greece)

HALL COSMOS

14.00-15.45

Concurrent Symposium I: Melanoma Genetics
Chairs: J. Newton-Bishop (UK), K. Peris (Italy), I. Stefanaki (Greece)

High and low penetrance genes in melanoma
N. Gruis (The Netherlands)

Pigmentation genes in melanoma susceptibility
M.C. Fargnoli (Italy)

A phenotype switching model for melanoma progression: implications for therapy
R. Dummer (Switzerland)

Molecular epidemiology of melanoma
J. Bauer (Germany)

Genetic determinants of disease progression and survival in melanoma
J. Newton-Bishop (UK)

Genetic testing and patient counseling in melanoma
S. Puig (Spain)

HALL ATLAS A

14.00-15.30

Concurrent Symposium II: Imaging techniques in melanoma diagnosis and management
Chairs: G. Pellacani (Italy), A. Tosca (Greece)

Dermoscopic features of early melanoma
I. Zalaudek (Austria)

Confocal microscopy
G. Pellacani (Italy)

HALL IRIS

14.00-15.30

Free Communications I: Epidemiology, pathogenesis and diagnosis of melanoma
Chair: H. Tsao (USA), J. Olah (Hungary), D. Polydorou (Greece)

FC1
Cutaneous melanoma and endogenous hormonal factors: a large French prospective cohort study
M. Kvaskoff, A. Bijon, S. Mesrine, M.-C. Boutron-Ruault,
F. Clavel-Chapelon

FC2
Oncogenic B-RAF signalling confers the resistance of metasatic melanoma to autophagy
J.L. Armstrong, M. Corazzari, M. Piacentini,
P.E. Lovat

FC3
Assessment of growth rate of melanomas based on sequential dermatoscopic images
L. Xu, H. Kittler

FC4
Foods rich in polyphenols and N-3 fatty acids decrease cutaneous melanoma risk 
C. Fortes, S. Mastroeni, F. Melchi, M.A. Pilla, G. Antonelli, D. Camaioni, M. Alotto, P. Pasquini
           
FC5
Incidence and trends of cutaneous malignancies in The Netherlands, 1989-2005
C. Holterhues, E. de Vries, M. Louwman, S. Koljenovic, T. Nijsten

FC6
Association of melanoma risk factors with body site, histological subtype, and primary melanoma count in a Flemish melanoma population (Belgium)
V. Marasigan, A. Ivanova, M. Stas, J. Van den Oord, M. Garmyn

FC7
Role of lymph-node ultrasonography (US) in the follow-up of melanoma patients to detect nodal recurrence after sentinel lymph node biopsy (SNLB): a prospective cohort study
P. Saiag, C. Lebbe, N. Basset-Seguin, P. Wolkenstein, N. Dupin, V. Descamps, S. Aractingi, O. Verola, L. Pinquier, T. Weng, P. Martel,
P. Aegerter

FC8
Efficiency of total body 18F PET/CT in the detection of cerebral metastases in patients with advanced melanoma
F. Vandenbroucke, B. Neyns, S. Deryk, A. Vanbinst, S. Wilgenhof,
L. Pierret, M. De Ridder, C. Vanhove, H. Everaert

FC9
Comprehensive review and field synopsis of genetic associations in cutaneous melanoma
F. Chatzinasiou, C. Lilli, K. Kypraiou, I. Stefanaki, V. Nicolaou, G. Spyrou, E. Evangelou, J. Roehr, E. Kodela, A. Katsambas, J. Ioannidis,
L. Bertram, A. Stratigos

15.30-16.00

Break

HALL COSMOS

16.00-17.30

Satellite Symposium I: What’s New in Melanoma?
Organized by:  

Chair: A. Hauschild (Germany)

Are we screening the right population for melanoma? 
A. Stratigos (Greece)

AJCC melanoma classification 2010: what has changed?        
A. Hauschild (Germany)

Selection of patients for adjuvant treatment                            
H. Gogas (Greece)

Advanced metastatic melanoma: highlights of ASCO 2010      
C. Garbe (Germany)

HALL COSMOS

17.30-19.15

Plenary Session III: Evolving issues on melanoma staging and management
Chairs: M. Ross (USA), M. Mihm (USA), O. Zoras (Greece)

Histopathological and molecular markers of prognosis
M. Mihm (USA)

An evidence-based approach to excision margins of melanoma
M. Ross (USA)

Lessons learned from clinical trials of sentinel node biopsy
V. Sondak (USA)

Evidence-based revisions to the AJCC/UICC melanoma staging system - 2010
J. Gershenwald (USA)

Management of in-transit metastases in melanoma: state-of the art
J. Marsden (United Kingdom)

FRIDAY, JUNE 18, 2010 

HALL COSMOS

08.00-09.30

Plenary Session IV: Current status of adjuvant therapy in melanoma
Chairs: J. Kirkwood (USA), H. Gogas (Greece), D. Tsoutsos (Greece)

Biology of metastasis in melanoma
C. Garbe (Germany)

How much more surgery is necessary after identifying a positive lymph node in melanoma?
V. Sondak (USA)

Response predictors to adjuvant therapy
H. Gogas (Greece)

Adjuvant therapy of melanoma - from chemotherapy and cytokines/interferons, to vaccines of high specificity and immunogenicity
J. Kirkwood (USA)

HALL COSMOS

09.30-10.00

Keynote address II
Chair: Α. Dimopoulos (Greece), B. Dreno (France)

Targeted treatment modalities for skin cancer
A. Hauschild (Germany)

10.00-10.30

Break

HALL COSMOS

10:30-12:00

Satellite Symposium II: Novel immunotherapeutic approaches in advanced melanoma

Organized by:  

Chairs: A. Hauschild (Germany), D. Schadendorf (Germany)

Melanoma and immune system
C. Robert (France)

Challenges of immunotherapy in melanoma
R. Dummer (Switzerland)

Evolution of immunotherapy in advanced melanoma
A. Hauschild (Germany)

Panel discussion
D. Schadendorf (Germany)

HALL COSMOS

12.15-13.45

Lunch session II: New Treatment approaches in actinic keratoses and NMSC

Sponsored by: 

Chairs: E. Stockfleth (Germany), C. Morton (UK), I. Bassoukas (Greece)

The concept of field cancerization
E. Stockfleth (Germany)

Imiquimod
G. Jemec (Denmark)

Solaraze
R. Kunstfeld (Austria)

Update on Photodynamic Therapy
C. Morton (UK)

New agents in the pipeline for the treatment of non-melanoma skin cancer
E. Stockfleth (Germany)

HALL COSMOS

14.00-15.30

Concurrent Symposium III: Novel strategies in melanoma immunotherapy
Chairs: B. Dreno (France), Κ. Frangia-Tsivou (Greece),
P. Stavropoulos (Greece)

Immunity and melanoma
K. Frangia-Tsivou (Greece)

Vaccine Immunotherapy and prognostic factors of success: where we are today?
B. Dréno (France)

Dendritic cell vaccination in melanoma
G. Schuler (Germany)

Adoptive cell therapy in melanoma
S. Martin Algarra (Spain)

Anti-CTLA4 antibody treatment
D. Schadendorf (Germany)

HALL ATLAS A

14.00-15.45

Concurrent Symposium IV: Melanoma - skin cancer Screening
Chairs: A. Geller (USA), V. del Marmol (Belgium), D. Sotiriadis (Greece)

Current approaches in melanoma screening
P. Arenberger (Czech Republic)

Melanoma screening: The Australian perspective
D. Whiteman (Australia)

Early detection of melanoma: Targeting high-risk individuals
A. Geller (USA)

Skin cancer/melanoma screening: the Euromelanoma experience
V. del Marmol (Belgium)

Nationwide Skin cancer screening in Germany
E. Breitbart (Germany)

Melanoma prevention in Eastern Europe
A.M. Forsea (Romania)

HALL IRIS

14.00-15.30

Free Communications II: Prognostic assessment and therapeutic approaches in melanoma
Chair: J.J. Grob (France), C. Robert (France), V. Chasapi (Greece)

FC10
Sorafenib and pegylated interferon - alpha 2b in advanced metastatic melanoma: A multicenter phase II DeCOG trial
A. Hauschild, R. Gutzmer, S. Ugurel, U. Trefzer, F. Egberts, J. Hassel,
D. Schadendorf, C. Mauch, C. Garbe, M. Weichenthal

FC11
Does systemic treatment prior to completion lymph node dissection influence surgical outcomes in stage III melanoma patients?
N. Kounalakis, R. Gonzalez, M.A. Becker, K.D. Lewis, A. Christenson,
N. Pearlman, W. Robinson, M. McCarter

FC12
Long term follow-up of 72 melanoma patients after intratumoral treatment with interleukin-2: favorable survival and high rate of objective responses upon subsequent chemotherapy 
B. Weide, T.K. Eigentler, A. Pflugfelder, F. Meier, U. Leiter, P. Radny,
C. Pfohler, C. Garbe

FC13
DERMA Phase III trial of MAGE-A3 immunotherapy as adjuvant treatment in stage III melanoma: MAGE-A3 gene expression frequency and baseline demographics
U. Trefzer, T. Jouary, C. Robert, M. Santinami, E. Levchenko, B. Smithers, A. Testori, O. Peeters, J. Kirkwood, B. Dreno

FC14
First-line Dacarbazine (DTIC) plus Bevacizumab (B) combination therapy in advanced melanoma (MM) patients (pts): a phase II study
A. Testori, A. di Pietro, E. Munzone, M. Mosconi, S. Gandini, C. Passoni, F. Verrecchia, I. Minchella, F. Nole, P.F. Ferrucci

FC15
Combination of Dacarbazine and Dimethylfumarate efficiently reduces melanoma lymph node metastasis
T. Valero, S. Steele, K. Neumueller, A. Bracher, H. Niederleithner,
H. Pehamberger, P. Petzelbauer, R. Loewe

FC16
A prospective randomised trial of sentinel node biopsy for high risk non-melanoma skin cancer (SNIC TRIAL)
R.C.W. Martin, W. Kelder, K. Roth, R. Murali,
R. Uren, A. Martin, J. Clark

FC17
SLN status in the prognosis of cutaneous primary malignant melanoma
M. Governa, F. Bosco, E. Vigato, L. Rossati, D. Grigolato, M. Zannoni,
P. Rosina

FC18
Clinical outcome following therapeutic vaccination with autologous mRNA electroporated dendritic cell vaccines in patients with advanced melanoma
L. Pierret, B. Neyns, S. Wilgenhof, D. Lienard, A. De Coninck,
J. Corthals, A. Bonehill, D. Roseeuw, V. del Marmol, K. Thielemans

FC19
Index risk on sentinel lymph nodes features that could predict non-sentinel lymph node involvement, disease-free survival and overall survival in melanoma patients
P. Quaglino, S. Ribero, L. Macri, A. Sapino, S. Osella-Abate, M. Grassi, V. Caliendo, P. Savoia, A. Sapino, G. Macripo, M.G. Bernengo

15.30-16.00

Break

HALL COSMOS

16.00-17.30

Satellite Symposium III: Adjuvant melanoma therapy – Towards a tailored solution for the patient

Organized by:

Chairs:  A. Hauschild (Germany), B. Dreno (France)
 
[Re]defining Stage III melanoma – Impact on prognosis and clinical decision-making
J. Gershenwald (USA)

Biomarkers in Melanoma – Facilitating a tailored adjuvant approach?
J. Becker (Germany)

Improving melanoma outcomes post-resection – Is a tailored solution close?

Appraising the efficacy of interferon in the management of resected melanoma
A. Hauschild (Germany)

Rationale for targeting melanoma with adjuvant monoclonal antibody therapy
C. Robert (France)

Revisiting immunotherapy – From adoptive transfer to tailored antigen-specific approaches
B. Dreno (France)

A surgeon’s view of advances in immunotherapy for melanoma: advances, past failures and future directions
M. Ross (USA)

Q & A and conclusion
Chairpersons

HALL COSMOS

17:30-19:15

Plenary Session V : Advances in the treatment of metastatic melanoma: from chemotherapy to targeted treatments
In association with the HELLENIC SOCIETY FOR MELANOMA RESEARCH
Chair: H. Pehamberger (Austria), K. Flaherty (USA), D. Bafaloukos (Greece)

Chemotherapy in melanoma (to be confirmed)
M. Middleton (UK)

Pro-apoptotic and anti-angiogenetic factors
H. Pehamberger (Austria)

Molecular markers predictive for an individualized therapy
S. Ugurel (Germany)

Targeting signal transduction pathways in melanoma
K. Flaherty (USA)

Regional perfusion in the treatment of metastatic disease
J. Pingpank (USA)

HALL ATLAS A

Satellite Symposium of the European Skin Cancer Foundation

Non Melanoma Skin Cancer: are we estimating the impact on society?

Introduction of the European Skin Cancer Foundation
Eggert Stockfleth (Germany)

Epidemiology of non-melanoma skin cancer-an underestimated health burden
Andreas Stang (Germany)

Prevention of non-melanoma skin cancer-where should we start?
Eggert Stockfleth (Germany)

Update on diagnosis and treatment of non-melanoma skin cancer
Gillian Murphy (Ireland)

Closing remarks
Eggert Stockfleth (Germany)

SATURDAY, JUNE 19, 2010  

HALL COSMOS

08.30-10.15

Concurrent Symposium V: Cutaneous T-cell lymphoma: how to diagnose and how to manage?
Chairs: R. Knobler (Austria), M. Bagot (France), I. Lefaki (Greece)

Classification and molecular pathogenesis of CTCL
M. Siakantari (Greece)

Guidelines for the treatment of cutaneous T-cell lymphoma
R. Stadler (Germany)

Treatment advances in cutaneous T-cell lymphomas
A. Cozzio (Switzerland)

Photopheresis in the treatment o the erythrodermic CTCL patient
R. Knobler (Austria)

Managing the CD30 + lymphoproliferative diseases
M. Bagot (France)

Unusual variants of cutaneous lymphomas
E. Papadavid (Greece)

HALL IRIS

08.30-10.00

Concurrent Symposium VI: Skin cancer in transplant patients
Chairs: J. Kanitakis (France), G. Murphy (Ireland), E. Toumbi (Greece)

The pathogenesis of skin cancer in the immunosuppressed: does it differ?
G. Hofbauer (Switzerland)

The spectrum of cutaneous malignancies in the transplant setting
J. Kanitakis (France)

Managing skin cancer in the immunosuppressed: clinical guidelines
C. Ulrich (Germany)

Enhancing sun protection measures in transplant patients
J. Hercogova (Czech Republic)

Challenging cases of transplantion dermatology
R.A. Johnson (USA)

HALL ATLAS A

09.00-16.00

Advanced Course on Dermatoscopy

Directors: C. Garbe (Germany), H. Kittler (Austria), J. Malvehy (Spain)

Speakers: G. Argenziano (Italy), G. Chaidemenos (Greece),
D. Loannidis (Greece), E. Lazaridou (Greece), S. Puig (Spain),
I. Zalaudek (Austria)

For detailed programme please click here

10.00-10.30

Break

HALL COSMOS

10.30-12.15

Plenary Session VI: Epidemiology and pathogenesis of NMSC
Sponsored by:

Chairs: G. Murphy (Ireland), A. Costanzo (Italy), N. Stavrianeas (Greece)

Epidemiologic perspective of NMSC in Europe
M. Trakatelli (Greece)

Genetic basis of epithelial skin carcinomas
A. Costanzo (Italy)

The role of HPV in cutaneous carcinoma
G. Murphy (Ireland)

Merkel cell Polyomavirus: emerging role as a new human tumor virus in the pathogenesis of Merkel cell carcinoma
A. Zur Hausen (Germany)

Epidemiology and pathogenesis of Kaposi sarcoma, what have we learnt recently?
C. Lebbe (France)

Preventive measeures in skin cancer: what's new?
E. Stockfleth (Germany)

HALL IRIS

10.30-12.15

Free Oral Communications III: Epidemiology and clinical management of NMSCs
Chair: G. Jemec (Denmark), I. Longo (Spain), A. Katoulis (Greece)

FC20
Three non-invasive treatment options for superficial basal cell carcinoma: photodynamic therapy versus Imiquimod versus 5-fluorouracil. TTOP-sBCC Trial
A.H.M.M. Arits, K. Mosterd, P. Nelemans, M.J. de Rooij, G.A. Krekels, P.J. Quaedvlieg, P.A.F. van Neer, A.J. van Geest, J.J. Rijzewijk, M.R. Hendriks, B.A. Essers, P.M. Steijlen, A. Sommer, N.J.W. Kelleners-Smeets

FC21
Clinical, histological and demographic predictors for recurrence and second primary tumour of head and neck basal cell carcinoma. A 1062 patient-cohort study from a tertiary cancer referral hospital
Aim. Lallas, E. Vakirlis, A. Kyrgidis, K. Vahtsevanos, T.G. Tzellos, P. Xirou, K. Kitikidou, K. Antoniades, C. Zouboulis, S. Triaridis

FC22
3.0% diclofenac in 2.5% hyaluronic acid inverts the process of cancerous transformation in actinic keratoses and maintains therapeutic response by prolongation of treatment
T. Dirschka, E. Bierhoff, A. Pflugfelder, C. Garbe

FC23
Treatment of Actinic Keratosis with 5-ALA PDT versus topical Imiquimod in healthy and immunosuppressed patients
M. Tsoukas

FC24
LDE225, a specific smoothened inhibitor, for the topical treatment of nevoid basal cell carcinoma syndrome (Gorlin's syndrome)
A. Stuetz, M.A. de Rie, H. Skvara, L. Mickel, C. Schuster, G. Stary,
F. Kalthoff, O.J. David, K. Rose, G. Stingl

FC25
IL-18 promoter variations at position -607 C/A is associated with individuals susceptibility to basal cell carcinoma
A. Kookhaei, S.H. Vakili, N. Erfani, M.R. Haghshenas, R. Salmanpour,
A. Ghaderi

FC26
Efficacy of immunocryosurgery in 105 consecutive, non-superficial basal cell carcinomas
G. Gaitanis, I. Bassukas

FC27
Nodular basal cell carcinoma is associated with increased hyaluronan homeostasis
T. Tzellos, A. Kyrgidis, K. Vahtsevanos, S. Triaridis, A. Printza, I. Klagas, E. Zvintzou, A. Kritis, G. Karakiulakis, E. Papakonstantinou

FC28
Characterization of the small T Antigen in Merkel cell-associated polyomavirus in Merkel cell carcinogenesis
H. Nguyen, P. Rady, S. Tyring

FC29
Electrochemotherapy (ECT) as a new anticancer therapeutic modality: the Hellenic Group of ECT (HeGECT) experience
G. Kyrgias, E. Mosa, E. Filopoulos, G. Kokalis, A. Lepouras, E. Zafiriou, M. Papamanthos, K. Theodorou, K. Kappas, J. Skarlatos

F30
An epidemiologic study of prevalent risk factors of basal cell carcinoma in the Greek population
C. Dessinioti, V. Sypsa, K. Tzannis, A. Hatzakis, A. Katsambas, C. Antoniou, K. Kypraiou, M. Sakoufaki, A.J. Stratigos

HALL COSMOS

12.30-14:00

Lunch Session III: Diagnosing and managing cutaneous toxicities of molecular targeted therapies in cancer
Sponsored by:

Chairs: C. Robert (France), C. Syrigos (Greece)

Mechanism, clinical features and therapy of EGFR inhibitors
C. Robert (France)
 
Mechanism, clinical features and therapy of angiogenesis inhibitors
V. Sibaud (France)

Mechanism, clinical features and therapy of MEK inhibitors - induced skin toxicities
R. Dummer (Switzerland)

Avène brand involvement in Oncologie
L. Phili (Greece)

HALL COSMOS

14:15-16:15

Closing session: Clinical and therapeutic challenges in cutaneous oncology
Chairs: D. Schadendorf (Germany), C. Fleming (United Kingdom),
D. Papadopoulos (Greece)

How to manage patients with lentigo maligna?
C. Fleming (UK)

Current treatment practics in NMSC
K. Peris (Italy)

Managing high risk squamous cell carcinoma
I. Longo (Spain)

Histiocytic malignant neoplasms of the skin
D. Schadendorf (Germany)

Diagnosis and management of Merkel cell carcinoma
K. Krasagakis (Greece)

Advances in the treatment of Kaposi's sarcoma
I. Danopoulou (Greece)

16.15

Closing Ceremony